von Borstel & Associates Inc. Makes New $694,000 Investment in Abbott Laboratories $ABT

von Borstel & Associates Inc. purchased a new position in shares of Abbott Laboratories (NYSE:ABT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,520 shares of the healthcare product maker’s stock, valued at approximately $694,000.

Several other hedge funds have also made changes to their positions in the business. Norges Bank acquired a new stake in Abbott Laboratories in the 2nd quarter worth about $3,026,180,000. Laurel Wealth Advisors LLC increased its stake in shares of Abbott Laboratories by 13,347.0% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after acquiring an additional 6,011,891 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after acquiring an additional 4,713,135 shares during the period. Vanguard Group Inc. boosted its position in shares of Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after acquiring an additional 2,977,715 shares during the last quarter. Finally, First Trust Advisors LP increased its position in Abbott Laboratories by 180.7% during the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock worth $416,659,000 after purchasing an additional 1,972,097 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling

In related news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president owned 24,628 shares of the company’s stock, valued at $2,846,504.24. The trade was a 2.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock valued at $353,097 over the last three months. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Down 0.1%

Shares of NYSE ABT opened at $107.99 on Friday. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.06. The company has a market cap of $187.66 billion, a P/E ratio of 29.03, a P/E/G ratio of 1.72 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock has a fifty day moving average price of $114.58 and a 200 day moving average price of $123.91.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the firm posted $1.34 earnings per share. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Analyst Ratings Changes

ABT has been the topic of a number of research analyst reports. Barclays decreased their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. Daiwa Securities Group reduced their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Evercore reduced their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Finally, BTIG Research dropped their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.